UNIVERSITY OF NORTH CAROLINA HOSPITALS

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1989-01-01

Employees: -

Market Cap: -

Website: http://www.unc.edu/interactive-tour/unc-hospitals/

Clinical Trials

Disease Outcomes and Toxicities in Patients With Gastrointestinal and Sarcomatous Malignancies

Recruiting

Conditions: Gastrointestinal Cancer
Sarcoma

Interventions: Other: Survey
Other: Toxicity Assessments

First Posted Date: 2023-02-24

Last Posted Date: 2024-03-22

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 180

Registration Number: NCT05743426

Locations: 🇺🇸
University of North Carolina at Chapel Hill, Department of Radiation Oncology, Chapel Hill, North Carolina, United States

Engaging Clinical Champions to Improve HPV Vaccination

Not Applicable

Conditions: Human Papilloma Virus

Interventions: Behavioral: Champion Announcement Approach Training
Behavioral: Traditional Announcement Approach Training

First Posted Date: 2023-02-21

Last Posted Date: 2024-04-30

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 40

Registration Number: NCT05736718

Locations: 🇺🇸
University of Wisconsin - Madison, Madison, Wisconsin, United States
🇺🇸
The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

Risk Stratification for Patients With Hospital-diagnosed Advanced Lung Cancer

Active, not recruiting

Conditions: Lung Cancer

First Posted Date: 2023-02-10

Last Posted Date: 2024-07-16

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 18

Registration Number: NCT05722847

Locations: 🇺🇸
UNC Lineberger, Chapel Hill, North Carolina, United States

Young Adult Infusion Space Experience Satisfaction Survey

Recruiting

Conditions: Cancer

Interventions: Other: Baseline Survey
Other: Semi-structured interviews
Other: Follow-up Survey

First Posted Date: 2023-02-09

Last Posted Date: 2024-03-08

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 100

Registration Number: NCT05720546

Locations: 🇺🇸
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

CD30 CAR for CD30+ NSGCT

Phase 2

Recruiting

Conditions: Germ Cell Tumor
Nonseminomatous Germ Cell Tumor

Interventions: Biological: ATLCAR.CD30 Cells
Drug: Cyclophosphamid
Drug: Fludarabine

First Posted Date: 2022-12-02

Last Posted Date: 2024-10-26

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 18

Registration Number: NCT05634785

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, United States

ctDNA in Subjects With Muscle-invasive Bladder Cancer Treated With Trimodality Therapy

Active, not recruiting

Conditions: Muscle-Invasive Bladder Carcinoma
Bladder Cancer

First Posted Date: 2022-11-29

Last Posted Date: 2024-03-26

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 20

Registration Number: NCT05630131

Locations: 🇺🇸
North Carolina Cancer Hospital (UNC), Chapel Hill, North Carolina, United States

Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer

Early Phase 1

Recruiting

Conditions: Non Small Cell Lung Cancer
Lung Cancer
Small Cell Lung Carcinoma

Interventions: Biological: iC9.GD2.CAR.IL-15 T Infusion

First Posted Date: 2022-11-17

Last Posted Date: 2024-10-24

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 24

Registration Number: NCT05620342

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

UNC Pleural Fluid Registry

Recruiting

Conditions: Breast Cancer
Empyema
Malignant Pleural Effusion
Lung Cancer
Lung Infection

First Posted Date: 2022-11-17

Last Posted Date: 2024-10-14

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 9999

Registration Number: NCT05620329

Locations: 🇺🇸
UNC Lingeberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

PRO-VISION: Patient Reported Outcomes-Based Monitoring of VEGF-Inhibitor Side Effects in ONcology

Not Applicable

Recruiting

Conditions: Renal Cell Carcinoma

Interventions: Other: Survey Questionnaire

First Posted Date: 2022-10-25

Last Posted Date: 2024-03-05

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 42

Registration Number: NCT05592665

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

Study of Trilaciclib and Lurbinectidin

Phase 2

Recruiting

Conditions: Small-cell Lung Cancer
Lung Cancer

Interventions: Drug: Trilaciclib
Drug: Lurbinectedin

First Posted Date: 2022-10-13

Last Posted Date: 2024-06-28

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 30

Registration Number: NCT05578326

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy